• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Wednesday's Pre-Market Session

    9/20/23 9:06:06 AM ET
    $AKLI
    $BJDX
    $ELUT
    $EXAI
    Medical/Dental Instruments
    Health Care
    Medical/Dental Instruments
    Health Care
    Get the next $AKLI alert in real time by email

    Gainers

    • Bluejay Diagnostics (NASDAQ:BJDX) shares moved upwards by 70.6% to $5.29 during Wednesday's pre-market session. The company's market cap stands at $6.5 million.
    • TransCode Therapeutics (NASDAQ:RNAZ) stock moved upwards by 53.94% to $0.81. The market value of their outstanding shares is at $1.6 million.
    • Fresh Tracks Therapeutics (NASDAQ:FRTX) stock increased by 52.68% to $0.89. The market value of their outstanding shares is at $5.2 million.
    • Histogen (NASDAQ:HSTO) shares increased by 29.93% to $0.51. The market value of their outstanding shares is at $2.1 million.
    • MSP Recovery (NASDAQ:LIFW) shares rose 28.12% to $0.12. The market value of their outstanding shares is at $39.9 million.
    • Exscientia (NASDAQ:EXAI) shares increased by 23.12% to $6.23. The market value of their outstanding shares is at $774.0 million.

    Losers

    • Seelos Therapeutics (NASDAQ:SEEL) stock decreased by 65.6% to $0.34 during Wednesday's pre-market session. The market value of their outstanding shares is at $44.0 million.
    • ARS Pharmaceuticals (NASDAQ:SPRY) shares decreased by 54.58% to $3.0. The company's market cap stands at $286.7 million.
    • Elutia (NASDAQ:ELUT) stock fell 15.76% to $1.39. The company's market cap stands at $22.5 million.
    • Heart Test Laboratories (NASDAQ:HSCS) stock fell 13.64% to $0.38. The market value of their outstanding shares is at $4.1 million. The company's, Q1 earnings came out 4 days ago.
    • Regulus Therapeutics (NASDAQ:RGLS) shares declined by 12.13% to $1.45. The market value of their outstanding shares is at $28.2 million.
    • Akili (NASDAQ:AKLI) shares fell 12.13% to $0.65. The company's market cap stands at $50.8 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AKLI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AKLI
    $BJDX
    $ELUT
    $EXAI

    CompanyDatePrice TargetRatingAnalyst
    ARS Pharmaceuticals Inc.
    $SPRY
    11/4/2025$30.00Buy
    Roth Capital
    ARS Pharmaceuticals Inc.
    $SPRY
    9/4/2025$40.00Buy
    Roth Capital
    Regulus Therapeutics Inc.
    $RGLS
    3/27/2025$3.00 → $6.00Equal Weight → Overweight
    Wells Fargo
    ARS Pharmaceuticals Inc.
    $SPRY
    3/7/2025$30.00Sector Outperform
    Scotiabank
    ARS Pharmaceuticals Inc.
    $SPRY
    2/10/2025$40.00Outperform
    Oppenheimer
    ARS Pharmaceuticals Inc.
    $SPRY
    8/20/2024Overweight
    Cantor Fitzgerald
    ARS Pharmaceuticals Inc.
    $SPRY
    8/13/2024$18.00 → $22.00Outperform → Strong Buy
    Raymond James
    ARS Pharmaceuticals Inc.
    $SPRY
    8/12/2024$19.00 → $20.00Outperform
    Leerink Partners
    More analyst ratings

    $AKLI
    $BJDX
    $ELUT
    $EXAI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Rakin Kevin bought $74,200 worth of shares (70,000 units at $1.06), increasing direct ownership by 56% to 196,120 units (SEC Form 4)

    4 - ELUTIA INC. (0001708527) (Issuer)

    2/2/26 5:01:40 PM ET
    $ELUT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Neels Guido J bought $20,800 worth of shares (20,000 units at $1.04), increasing direct ownership by 20% to 118,750 units (SEC Form 4)

    4 - ELUTIA INC. (0001708527) (Issuer)

    2/2/26 8:43:47 AM ET
    $ELUT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Neels Guido J bought $31,800 worth of shares (30,000 units at $1.06), increasing direct ownership by 44% to 98,750 units (SEC Form 4)

    4 - ELUTIA INC. (0001708527) (Issuer)

    1/29/26 5:51:15 PM ET
    $ELUT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AKLI
    $BJDX
    $ELUT
    $EXAI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Elutia Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

    GAITHERSBURG, Md., March 13, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that it granted equity awards on March 10, 2026 to three new employees as inducement awards under the Elutia Inc. 2026 Inducement Award Plan (the "Plan"). The awards were approved by the independent Compensation Committee of the Board of Directors, and were granted in accordance with Nasdaq Listing Rule 5635(c)(4). Under the Plan, the three new employees received an aggregate of 460,000 non-qualified stock options (the "Options"). The Options vest 25% on the first anniversary of the vesting commencement date, with th

    3/13/26 8:00:00 AM ET
    $ELUT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Bluejay Announces Abstract Accepted for Presentation at the 2026 Society of Academic Emergency Medicine (SAEM) Annual Meeting

    ACTON, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ:BJDX) ("Bluejay" or the "Company"), a medical diagnostics company developing rapid near-patient tests for critical care conditions, today announced that an abstract related to its Symphony™ IL-6 Test has been accepted for presentation at the 2026 Society of Academic Emergency Medicine (SAEM) Annual Meeting, which will take place May 18–21, 2026 in Atlanta, Georgia. The presentation will report findings from SYMON-I, a multicenter pilot clinical study evaluating interleukin-6 (IL-6) levels in patients with sepsis who were admitted or intended for admission to the intensive care unit (ICU). The analysis evalu

    3/12/26 6:30:00 AM ET
    $BJDX
    Medical/Dental Instruments
    Health Care

    Elutia Reports Fourth Quarter and Full Year 2025 Financial Results; Initiates NXT-41 Regulatory Process

    – Base biologic matrix NXT-41 submitted to FDA; on track for anticipated FDA clearance in second half of 2026 and full NXT-41x clearance in 1H27 – – $44.4 million in cash and escrowed proceeds at year-end – – Conference call today at 5:00 p.m. ET / 2:00 p.m. PT – GAITHERSBURG, Md., March 11, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today provided a business update and financial results for the fourth quarter and full year ended December 31, 2025. Business Highlights: NXT-41x Development Program On Track: Elutia continues to advance development of NXT-41x, a next-generation antibiotic-eluting bioma

    3/11/26 4:05:00 PM ET
    $ELUT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AKLI
    $BJDX
    $ELUT
    $EXAI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Roth Capital resumed coverage on ARS Pharmaceuticals with a new price target

    Roth Capital resumed coverage of ARS Pharmaceuticals with a rating of Buy and set a new price target of $30.00

    11/4/25 8:07:28 AM ET
    $SPRY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Roth Capital initiated coverage on ARS Pharmaceuticals with a new price target

    Roth Capital initiated coverage of ARS Pharmaceuticals with a rating of Buy and set a new price target of $40.00

    9/4/25 7:57:34 AM ET
    $SPRY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Regulus Therapeutics upgraded by Wells Fargo with a new price target

    Wells Fargo upgraded Regulus Therapeutics from Equal Weight to Overweight and set a new price target of $6.00 from $3.00 previously

    3/27/25 1:44:29 PM ET
    $RGLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKLI
    $BJDX
    $ELUT
    $EXAI
    SEC Filings

    View All

    Bluejay Diagnostics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Bluejay Diagnostics, Inc. (0001704287) (Filer)

    3/16/26 6:07:57 AM ET
    $BJDX
    Medical/Dental Instruments
    Health Care

    SEC Form 10-K filed by Elutia Inc.

    10-K - ELUTIA INC. (0001708527) (Filer)

    3/13/26 4:11:15 PM ET
    $ELUT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Bluejay Diagnostics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Bluejay Diagnostics, Inc. (0001704287) (Filer)

    3/12/26 12:24:37 PM ET
    $BJDX
    Medical/Dental Instruments
    Health Care

    $AKLI
    $BJDX
    $ELUT
    $EXAI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF SCIENTIFIC OFFICER Williams Michelle Leroux converted options into 12,500 shares and covered exercise/tax liability with 4,613 shares, increasing direct ownership by 8% to 109,821 units (SEC Form 4)

    4 - ELUTIA INC. (0001708527) (Issuer)

    3/12/26 5:00:15 PM ET
    $ELUT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CHIEF FINANCIAL OFFICER Ferguson Matthew converted options into 12,500 shares and covered exercise/tax liability with 5,123 shares, increasing direct ownership by 2% to 472,067 units (SEC Form 4)

    4 - ELUTIA INC. (0001708527) (Issuer)

    3/12/26 5:00:12 PM ET
    $ELUT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    PRESIDENT AND CEO Mills C Randal converted options into 27,084 shares and covered exercise/tax liability with 11,100 shares, increasing direct ownership by 4% to 409,406 units (SEC Form 4)

    4 - ELUTIA INC. (0001708527) (Issuer)

    3/12/26 5:00:12 PM ET
    $ELUT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AKLI
    $BJDX
    $ELUT
    $EXAI
    Leadership Updates

    Live Leadership Updates

    View All

    Elutia Selects Pete Ligotti as CCO to Lead the Commercial Launch of NXT-41x and Transform Post-Mastectomy Care in the $1.5B U.S. Breast Surgery Market

    GAITHERSBURG, Md., March 02, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced the appointment of Pete Ligotti as Chief Commercial Officer. Mr. Ligotti will lead the commercialization for NXT-41x, Elutia's next-generation antibiotic-eluting biomatrix being developed to improve outcomes in plastic and reconstructive surgery. NXT-41x is Elutia's next-generation antibiotic-eluting biomatrix, built on the Company's validated drug-eluting platform. Elutia is applying that platform in plastic and reconstructive surgery, where breast reconstruction represents the largest and most underserved opportuni

    3/2/26 8:00:00 AM ET
    $ELUT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Where Purpose Meets Performance: Elutia Earns 2026 Great Place to Work Certification™

    GAITHERSBURG, Md., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that it has been Certified™ by Great Place to Work®, the leading organization that evaluates workplace culture through a standardized, anonymous employee survey methodology developed over 30 years of research. The certification recognizes organizations with high-trust workplace cultures, where sustained engagement and retention support consistent execution in regulated, innovation-driven industries. "Elutia isn't for everyone," said Dana Yoo, PhD, VP of Product Development. "The bar is high, and the work is hard. But

    2/18/26 8:00:00 AM ET
    $ELUT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    TransCode Therapeutics Expands Leadership with Appointment of Jack E. Stover to Board of Directors

    BOSTON, Dec. 22, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, announced the appointment of Jack E. Stover to its Board of Directors. Mr, Stover will join the Audit and the Nominating Committees as Dr. Magda Marquet steps down from the Audit Committee.  Mr. Stover brings more than three decades of executive leadership experience across public and private life sciences companies, spanning drug development, diagnostics, specialty pharmaceuticals, and capital formation.

    12/22/25 8:01:00 AM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKLI
    $BJDX
    $ELUT
    $EXAI
    Financials

    Live finance-specific insights

    View All

    ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Updates on neffy® (epinephrine nasal spray) Commercialization

    neffy delivers $72.2 million of U.S. net product revenue in first full year Intranasal epinephrine platform advances with Phase 2b CSU data expected mid-2026 Strong balance sheet of $245.0 million in cash, cash equivalents and short-term investments supports operating plan through anticipated cash-flow break-even  Conference call to be held today, March 9, 2026, at 5:30 a.m. PT / 8:30 a.m. ET SAN DIEGO, March 09, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis, today announced financial results for t

    3/9/26 6:00:00 AM ET
    $SPRY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elutia to Report Fourth Quarter 2025 Financial Results on Wednesday, March 11, 2026

    GAITHERSBURG, Md., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that it will release its fourth quarter 2025 financial results after market close on Wednesday, March 11, 2026. Members of the Company's management team will host a conference call and webcast starting at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time on the same day. The conference call can be accessed using the following information: Webcast: Click here Dial-In: Click here To receive the dial-in number, as well as your personalized PIN, you must register at the above link. Once registered, you will also have the

    2/25/26 4:05:00 PM ET
    $ELUT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2025 Financial Results and Participation at Upcoming Conferences

    SAN DIEGO, Feb. 23, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis, today announced the company will host a conference call and webcast on Monday, March 9, 2026 at 5:30 a.m. PT / 8:30 a.m. ET to discuss its fourth quarter and full year 2025 financial results and business highlights. Dial-in information for conference participants may be obtained by registering for the event. In addition, ARS Pharma Management will be participating at several upcoming investor conferences: 10th Annual Oppenheimer Emer

    2/23/26 8:00:00 AM ET
    $SPRY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKLI
    $BJDX
    $ELUT
    $EXAI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by MSP Recovery Inc.

    SC 13D/A - MSP Recovery, Inc. (0001802450) (Subject)

    12/17/24 4:05:04 PM ET
    $LIFW
    EDP Services
    Technology

    Amendment: SEC Form SC 13G/A filed by Seelos Therapeutics Inc.

    SC 13G/A - SEELOS THERAPEUTICS, INC. (0001017491) (Subject)

    12/4/24 1:29:12 PM ET
    $SEEL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Exscientia Plc

    SC 13G/A - Exscientia plc (0001865408) (Subject)

    11/22/24 9:11:55 PM ET
    $EXAI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care